PharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017

USA - English

• USA - Deutsch
• USA - Italiano

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
  

The abstract #1529 titled "Activity of lurbinectedin (PM1183) as single agent and in combination in patients with advanced small cell lung cancer (SCLC)" will be presented on September 11^th. In this abstract, a cohort B will be presented using a new dosing regimen as compared to cohort A that was presented at the American Society of Clinical Oncology Annual Meeting in 2015. The efficacy of PM1183 in this cohort of patients with advanced small cell lung cancer was evidenced by a progression free survival (PFS) of 5.3m with an objective response rate of 37%. The safety profile in Cohort B in terms of the rate of febrile neutropenia, thrombocytopenia and anemia was markedly improved compared to cohort A.

Lurbinectedin is currently enrolling the pivotal phase III ATLANTIS trial in this setting with an expected completion of enrollment around first half of 2018. Dr. Arturo Soto, Director of the Clinical Department at PharmaMar Oncology Business Unit, added "small cell lung cancer is a devastating disease and the only approved drug for advanced disease is Topotecan. As far as we know these results with lurbinectedin offer the longest PFS seen in this setting and we hope to be able to offer these patients a new treatment option, if we confirm this data in the pivotal clinical trial."

PM1183 

• Activity of lurbinectedin in SCLC (alone and in combination) from different phase I and phase II studies (#1529PD) 

Poster Discussion Session. 11.09.2017, 14:45 - 16:15, Pamplona Auditorium

Lead author: María Eugenia Olmedo, MD, et al. Ramón y Cajal Universitary Hospital, Madrid, Spain  

Paula Fernandez: Media Relations (+ 34 638 79 62 15) and Investor Relations (+34 914444500)

SOURCE PharmaMar